Contact Octapharma - NUWIQ®️ [Antihemophilic Factor (Recombinant)]

Octapharma USA, Inc.

117 W. Century Road
Paramus, NJ 07652

www.octapharmausa.com

P: 201-604-1130

Customer Service

For general questions about NUWIQ Antihemophilic Factor (Recombinant), reconstitution, product support, or this site, please contact Octapharma Customer Service.

P: 866-766-4860
E: uscustomerservice@octapharma.com

Reimbursement

For questions about reimbursement and insurance, please contact Octapharma Reimbursement. Our experienced and knowledgeable professionals are available to provide support to providers, patients, and families.

P: 855-498-4260

Drug Safety / Adverse Event Report

For all inquiries relating to drug safety, or to report adverse events, please contact our local Drug Safety Officer.

P: 201-604-1137
C: 201-772-4546
F: 201-604-1141

Medical Affairs

For a medical information request, please call Octapharma Medical Affairs.

P: 888-429-4535
E: usmedicalaffairs@octapharma.com

An Octapharma Medical Affairs representative will respond to your medical inquiry within 2 business days.

Indications and Important Safety Information for NUWIQ [Antihemophilic Factor (Recombinant)]

Please see NUWIQ full Prescribing Information. Instructions For Use

Indications and Important Safety Information for NUWIQ [Antihemophilic Factor (Recombinant)]

Please see NUWIQ full Prescribing Information. Instructions For Use

Indications and Use

NUWIQ^® is a recombinant antihemophilic factor [coagulation factor VIII (Factor VIII)] indicated in adults and children with Hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes. NUWIQ^® is not indicated for the treatment of von Willebrand Disease.

Contraindications

NUWIQ is contraindicated in patients who have manifested life-threatening hypersensitivity reactions, including anaphylaxis, to the product or its components.

Warnings and Precautions

Hypersensitivity reactions, including anaphylaxis, are possible with NUWIQ. Early signs of hypersensitivity reactions that can progress to anaphylaxis may include angioedema, chest tightness, dyspnea, wheezing, urticaria, or pruritus. Immediately discontinue administration and initiate appropriate treatment if hypersensitivity reactions occur.

The formation of neutralizing antibodies (inhibitors) to Factor VIII can occur following the administration of NUWIQ. Monitor all patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests. If the plasma Factor VIII level fails to increase as expected, or if bleeding is not controlled after NUWIQ administration, suspect the presence of an inhibitor (neutralizing antibody).

Adverse Reactions

The most frequently occurring adverse reactions (>5%) in clinical trials were upper respiratory tract infection, headache, fever, cough, lower respiratory tract infection, rhinitis, chills, abdominal pain, arthralgia, anemia, and pharyngitis.

Please See NUWIQ full Prescribing Information. Instructions For Use